Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks Durvalumab's safety and effectiveness in russian lung cancer patients

NCT ID NCT05456867

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 250 adults in Russia with advanced, inoperable non-small cell lung cancer who are receiving durvalumab after chemoradiation. Researchers will track side effects, treatment duration, and outcomes to see how the drug performs in routine clinical practice. The goal is to gather real-world data to help optimize treatment for these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab
What this could lead to
If successful, this study could help doctors understand how to better use durvalumab in everyday practice, potentially improving treatment plans for lung cancer patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by real-world factors. It cannot prove cause and effect, and findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study may include all patients who have received the first dose of durvalumab prior to study participation. To enter in the study, patients must have completed a platinum-based chemotherapy concurrently or sequentially with radiation therapy without evidence of disease progression. There is no fixed maximum duration for durvalumab treatment. Treatment with durvalumab continues until the physician determines that it is in the patient's best interest to stop therapy. It is expected to recruit 300 patients from approximately 25 cites.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the exclusion criteria apply: * Written informed consent obtained from the patient prior to performing any protocol-related procedures * Age ≥18 years at time of study entry * Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent, unresectable (stage III) disease (according to American Joint Committee on Cancer \[AJCC\] lung cancer edition 8) * Patients must have completed a platinum-based chemotherapy with radiation therapy (concurrent or sequential) without evidence of disease progression * Patients must have been treated with at least one dose of durvalumab Exclusion Criteria: Any subject who meets any of the following criteria will not qualify for entry into the study: * Absence or missing of written informed consent form * Patients treated with durvalumab in clinical studies * Absence of essential data to obtain all necessary information * Confirmation that the subject was already included in this study before

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (non-small cell lung carcinoma) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (non-small cell lung carcinoma)

Contacts and locations

Locations

  • Research Site

    Arkhangelsk, Russia

  • Research Site

    Chelyabinsk, Russia

  • Research Site

    Grozny, Russia

  • Research Site

    Irkutsk, Russia

  • Research Site

    Khanty-Mansiysk, Russia

  • Research Site

    Kostroma, Russia

  • Research Site

    Krasnodar, Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Murmansk, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Perm, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Sochi, Russia

  • Research Site

    Surgut, Russia

  • Research Site

    Tomsk, Russia

  • Research Site

    Ufa, Russia

  • Research Site

    Vologda, Russia

  • Research Site

    Yaroslavl, Russia

  • Research Site

    Yekaterinburg, Russia

  • Research Site

    Yuzhno-Sakhalinsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.